Stada Enjoys Robust First Half For Generics And Biosimilars
Recently Launched Higher-Strength 100mg/ml Adalimumab Biosimilar
With generics and biosimilars sales continuing to flow in the first half of 2022, Stada reported healthy top- and bottom-line growth for the first six months of the year, including a 23% rise for its adjusted EBITDA.
